| Description |
1 online resource (304 pages) |
| Series |
RSC Drug Discovery |
|
RSC drug discovery series
|
| Contents |
Cover ; Preface; Contents; Chapter 1 The Genetics of Schizophrenia ; 1.1 Introduction; 1.2 What Genetics Can Tell Us about Schizophrenia; 1.2.1 The Heritability of Schizophrenia; 1.2.2 The Genetic Architecture of Schizophrenia; 1.3 The Tools of Genomics; 1.4 What Genetics Has Told Us about Schizophrenia; 1.4.1 Common Variation; 1.4.1.1 Receptors; 1.4.1.2 The Major Histocompatibility Complex; 1.4.1.3 Kinases; 1.4.1.4 Calcium Channels; 1.4.1.5 Non-coding RNAs; 1.4.2 Rare Variation; 1.4.2.1 Disrupted in Schizophrenia 1 (DISC1); 1.4.2.2 Neurexin 1 (NRXN1) |
|
1.4.2.3 Vasoactive Intestinal Peptide Receptor 2 (VIPR2)1.4.2.4 Lessons from Sequencing Studies; 1.4.3 The Future of GWASs; 1.5 What Genetics is Telling Us about Schizophrenia; 1.6 The Limitations of Genetic Studies of Schizophrenia; 1.7 Conclusion; 1.8 Definitions; References; Chapter 2 The Impact of Epigenetics in Schizophrenia Research ; 2.1 Introduction; 2.2 Genetic Epidemiology: The Hunt for Genes Associated with Mental Disorders; 2.3 Where is the missing heritability; 2.4 Epigenetics: A New Memory System in Neurobiology; 2.4.1 DNA Methylation; 2.4.2 Histone Methylation |
|
2.4.3 Histone Acetylation2.4.4 Epigenetics of GABA-ergic Neurons and Neocortical Development; 2.5 Conclusions; References; Chapter 3 Developmental Neuroimmune Mechanisms in Schizophreia ; 3.1 Introduction; 3.2 Epidemiological and Translational Studies of Prenatal Infection and Schizophrenia; 3.3 The Role of Inflammation in Mediating the Effects of Maternal Infection in the Offspring; 3.3.1 The Main Components of the Inflammatory Response System; 3.3.2 Neurodevelopmental Effects of Cytokines |
|
3.3.3 Epidemiological Evidence for the Role of Inflammation in Mediating the Effects of Maternal Infection on the Offspring3.3.4 Experimental Evidence for the Role of Inflammation in Mediating the Effects of Maternal Infection on the Offspring; 3.4 Fetal Brain Development in the Event of Inflammation; 3.5 Priming of Long-term Neuroinflammation by Prenatal Infection and Inflammation; 3.6 (Latent) Neuroinflammation and Disease Progression; 3.7 Developmental Neuroinflammation as a Possible Target for Disease Prevention; 3.8 Conclusions; References |
|
Chapter 4 The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models 4.1 Substance Use and Schizophrenia: Clinical Aspects; 4.1.1 Epidemiology and Clinical Aspects; 4.1.2 Human Studies Exploring the Impact of Nicotine on Cognition in Schizophrenia; 4.1.3 Human Studies Exploring the Impact of Cannabis on Cognition in Schizophrenia; 4.2 Human Studies that Explore the Impact of Smoke on the Side-effects of Antipsychotic Medications; 4.3 Animal Models to Study the Self-medication Hypothesis; 4.3.1 Modelling Schizophrenia in Animals |
| Summary |
This book covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery |
| Notes |
4.3.1.1 Models of Positive Symptoms (Dopamine Hyperactivity) |
| Bibliography |
Includes bibliographical references at the end of each chapters and index |
| Notes |
English |
|
Print version record |
| Subject |
Schizophrenia -- Chemotherapy.
|
|
Drugs -- Design.
|
|
Antipsychotic drugs.
|
|
Chemotherapy.
|
|
Schizophrenia.
|
|
Tranquilizing drugs.
|
|
Pharmaceutical chemistry.
|
|
Therapeutics.
|
|
Central nervous system depressants.
|
|
Chemistry.
|
|
Psychotropic drugs.
|
|
Mental illness.
|
|
Pharmacology.
|
|
Physical sciences.
|
|
Life sciences.
|
|
Antipsychotic Agents
|
|
Drug Discovery
|
|
Drug Therapy
|
|
Schizophrenia
|
|
Tranquilizing Agents
|
|
Chemistry, Pharmaceutical
|
|
Therapeutics
|
|
Schizophrenia and Disorders with Psychotic Features
|
|
Investigative Techniques
|
|
Central Nervous System Depressants
|
|
Analytical, Diagnostic and Therapeutic Techniques and Equipment
|
|
Chemistry
|
|
Psychotropic Drugs
|
|
Mental Disorders
|
|
Pharmacology
|
|
Central Nervous System Agents
|
|
Psychiatry and Psychology
|
|
Natural Science Disciplines
|
|
Physiological Effects of Drugs
|
|
Biological Science Disciplines
|
|
Pharmacologic Actions
|
|
Disciplines and Occupations
|
|
Therapeutic Uses
|
|
Chemical Actions and Uses
|
|
Chemicals and Drugs
|
|
Drug Design
|
|
Schizophrenic Psychology
|
|
chemistry.
|
|
mental disorders.
|
|
pharmacology.
|
|
physical sciences.
|
|
biological sciences.
|
|
Psychiatry.
|
|
Chemistry.
|
|
MEDICAL -- Pharmacology.
|
|
SCIENCE -- Life Sciences -- Biochemistry.
|
|
Drugs -- Design.
|
|
Schizophrenia -- Chemotherapy.
|
| Form |
Electronic book
|
| Author |
Gebicke-Haerter, Peter
|
|
Gainetdinov, Raul
|
|
Ramsey, Amy
|
|
Lipina, Tatiana V
|
|
Meyer, Urs
|
|
Waddington, John
|
|
Gaisler-Salomon, Inna
|
|
Brandon, Nick
|
|
LeFoll, Bernard
|
|
Royal Society of Chemistry (Great Britain), Content Provider
|
| ISBN |
1782620265 |
|
9781782620266 |
|
9781782622499 |
|
1782622497 |
|
9781782625049 |
|
1782625046 |
|
